Paper
3 February 1999 Chlorins with six-membered imide ring as prospective sensitizers for cancer PDT
Andrei F. Mironov, Victoria S. Lebedeva, Raisa I. Yakubovskaya, Natalia I. Kazachkina, Galina I. Fomina
Author Affiliations +
Abstract
A series of promising PDT sensitizers having intensive absorption maximum at 710 - 750 nm has been synthesized from the readily available purpurin 18. Modification of an anhydride ring is purpurin 18 afforded two series of cyclic imides. The first group comprises the N-substituted derivatives containing residues of aliphatic alcohols (C2- C4) and carboxylic acids (C1, C5). The second series is represented by the cyclic N-hydroxyimides containing the -N-OR group, where R is either alkyl or acyl residue. Cyclic imides possess increased resistance to alkali treatment, which enhances their water solubility. They absorb in the region of 706 - 718 nm. Further development of the spectral characteristics was achieved by the oxidation of a 3- vinyl group into the formyl one. The obtained compounds have the absorption maximum in the region of 750 nm, which makes them comparable to those of bacteriochlorophyll derivatives. The presence of a spacer group in the molecule of compounds synthesized affords their attachment to the carriers for the directed transport of a sensitizer into tumor.
© (1999) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Andrei F. Mironov, Victoria S. Lebedeva, Raisa I. Yakubovskaya, Natalia I. Kazachkina, and Galina I. Fomina "Chlorins with six-membered imide ring as prospective sensitizers for cancer PDT", Proc. SPIE 3563, Photochemotherapy of Cancer and Other Diseases, (3 February 1999); https://doi.org/10.1117/12.339119
Lens.org Logo
CITATIONS
Cited by 12 scholarly publications.
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Photodynamic therapy

Tumors

Absorbance

Chlorine

Luminescence

Magnesium

Cancer

Back to Top